La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Bio-Path Holdings Dividendo

Dividendo criteri di controllo 0/6

Bio-Path Holdings non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore	1.9%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Utile per azione	-US$4.54
Previsione del rendimento del dividendo	n/a

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate

Nov 05

Bio-Path GAAP EPS of -$0.42 beats by $0.07

Aug 16

Is Bio-Path Holdings (NASDAQ:BPTH) In A Good Position To Deliver On Growth Plans?

Jul 08

Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation

Mar 24

Bio-Path Holdings (NASDAQ:BPTH) Is In A Good Position To Deliver On Growth Plans

Aug 17

We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully

Mar 26

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di BPTH siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di BPTH siano aumentati.

Rendimento dei dividendi rispetto al mercato

Bio-Path Holdings Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di BPTH rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (BPTH)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.3%
Media del settore (Biotechs)	1.9%
Analista previsionale (BPTH) (fino a 3 anni)	n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di BPTH rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di BPTH rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di BPTH per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché BPTH non ha segnalato alcun pagamento.

Bio-Path Holdings Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Recent updates

Bio-Path Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders’ Equity Requirement

Bio-Path Holdings, Inc. Reports Solid Tumor Patient Response Supporting BP1001-A's Compelling Potential as Treatment for Advanced Solid Tumors

New major risk - Financial position

Bio-Path Holdings, Inc. to Report Q2, 2024 Results on Aug 15, 2024

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At European Hematology Association Congress

Bio-Path Holdings, Inc. announced that it expects to receive $4.000001 million in funding

New major risk - Negative shareholders equity

Bio-Path Holdings, Inc. to Report Q1, 2024 Results on May 15, 2024

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.209375 million.

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.209375 million.

New major risk - Share price stability

Bio-Path Holdings, Inc. Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients

Bio-Path Holdings, Inc. Expands Global Patent Portfolio

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

New minor risk - Profitability

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $0.29925 million.

Bio-Path Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $7.499995 million.

Bio-Path Holdings Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(b)(1)

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $7.499995 million.

Bio-Path Holdings, Inc. to Report Q4, 2023 Results on Mar 08, 2024

Bio-Path Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $23.75 million.

New major risk - Share price stability

Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $19 million.

Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia

No longer forecast to breakeven

Bio-Path Holdings, Inc. to Report Q3, 2023 Results on Nov 15, 2023

Bio-Path Holdings, Inc., Annual General Meeting, Dec 14, 2023

Bio-Path Holdings, Inc. Receives Non-Compliance Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Price target decreased by 7.7% to US$12.00

Bio-Path Holdings, Inc. to Report Q2, 2023 Results on Aug 15, 2023

New major risk - Shareholder dilution

New major risk - Share price stability

Bio-Path Holdings, Inc. Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia

New major risk - Market cap size

New minor risk - Share price stability

Bio-Path Holdings, Inc. to Report Q1, 2023 Results on May 12, 2023

Forecast to breakeven in 2025

Bio-Path Holdings, Inc. Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors

Price target decreased to US$11.00

Bio-Path Holdings, Inc. to Report Q3, 2022 Results on Nov 15, 2022

We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate

Bio-Path Holdings, Inc., Annual General Meeting, Dec 15, 2022

Bio-Path Holdings, Inc. Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

Bio-Path GAAP EPS of -$0.42 beats by $0.07

Bio-Path Holdings, Inc. to Report Q2, 2022 Results on Aug 16, 2022

Is Bio-Path Holdings (NASDAQ:BPTH) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$11.00

Bio-Path Holdings, Inc. to Report Q1, 2022 Results on May 17, 2022

Price target increased to US$12.50

Less than half of directors are independent

Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual Meeting

Bio-Path Holdings, Inc. Appoints Aline Sherwood to its Board of Directors

Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation

Bio-Path Holdings, Inc. to Report Fiscal Year 2021 Results on Mar 11, 2022

Insufficient new directors

Bio-Path Holdings, Inc. Announces Resignation of Martina Molsbergen as Member of the Board and All Committees of the Board

Bio-Path Holdings, Inc. Presents Data from Ongoing Phase 2 Study of Prexigebersen At 2021 American Society of Hematology Annual Meeting

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

Bio-Path Holdings (NASDAQ:BPTH) Is In A Good Position To Deliver On Growth Plans

Price target increased to US$12.50

We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully

Bio-Path Holdings, Inc. to Report Fiscal Year 2020 Results on Mar 10, 2021

New 90-day high: US$4.55

Will Bio-Path Holdings (NASDAQ:BPTH) Spend Its Cash Wisely?

Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002

Dosing underway in Bio-Path's early-stage BP1002 study

Bio-Path EPS beats by $0.07

Bio-Path Holdings, Inc. to Report Q3, 2020 Results on Nov 13, 2020

Bio-Path Holdings, Inc., Annual General Meeting, Dec 17, 2020

New 90-day low: US$3.72

New 90-day low - US$3.86

Bio-Path Holdings, Inc. to Report Q2, 2020 Results on Aug 14, 2020

Bio-Path Holdings, Inc.(NasdaqCM:BPTH) dropped from Russell Microcap Growth Index

Bio-Path Holdings, Inc.(NasdaqCM:BPTH) dropped from Russell Microcap Index